-
Anhui Anke Biotechnology Receives NMPA Approval for Clinical Trial of HPV-Targeting mRNA Drug AFN0328
•
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its drug candidate AFN0328. This investigational mRNA drug targets tumors associated with human papillomavirus (HPV), particularly HPV16 and/or HPV18 in the cervix, which are…
-
Anhui Anke Biotechnology Receives NMPA Clearance for Clinical Trial of mRNA Drug AFN0328 for HPV-Related Cancers
•
Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009), a biopharmaceutical company based in China, has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its drug candidate AFN0328. The drug is intended for the treatment of malignant tumors associated with HPV16/18 infection, including cervical…
-
Shanghai Escugen and Anke Bio Partner to Develop ADC Products with EZWi-Fit Platform
•
Shanghai Escugen, a biopharmaceutical company based in China, has entered into a licensing and cooperation agreement with Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009). Under the terms of the agreement, Escugen will grant Anke Bio the rights to its antibody-drug conjugate (ADC) technology platform, EZWi-Fit, for the development of…
